Cheaper diabetes therapy on the horizon as semaglutide patent expires

The expiry of the patent on Semaglutide this month is set to open the door for a wave of lower-cost alternatives in India, potentially reshaping access to treatment for millions living with diabetes and obesity.

Industry estimates suggest that more than 50 generic versions of the drug could enter the market in the coming months. This is expected to significantly reduce prices, which have so far limited widespread use despite the drug’s proven efficacy in managing blood sugar levels and aiding weight loss.

India carries a substantial burden of diabetes, often referred to as the diabetes capital of the world. For patients, particularly those in middle- and lower-income groups, affordability remains a decisive factor in long-term treatment adherence. A drop in prices could therefore translate into better disease management outcomes at scale.

However, the transition to generics will also require regulatory vigilance. Ensuring quality, bioequivalence and consistent supply across manufacturers will be critical to maintaining patient trust. Physicians, too, may need to navigate a crowded market as multiple brands compete for prescriptions.

The development reflects a broader pattern in India’s pharmaceutical landscape, where patent expiries often trigger rapid expansion of the generics segment. If managed well, the entry of affordable semaglutide could mark a meaningful step in improving access to modern diabetes care without escalating healthcare costs.